

SAMPLE CODING

Alveolar Soft Part Sarcoma (ASPS)

| TYPE | CODE | DESCRIPTION |
|--|---|--|
| Diagnosis: ICD-10-CM | C49.0 | Malignant neoplasm of connective and soft tissue of head, face and neck |
| | C49.11 | Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder |
| | C49.12 | Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder |
| | C49.21 | Malignant neoplasm of connective and soft tissue of right lower limb, including hip |
| | C49.22 | Malignant neoplasm of connective and soft tissue of left lower limb, including hip |
| | C49.3 | Malignant neoplasm of connective and soft tissue of thorax |
| | C49.4 | Malignant neoplasm of connective and soft tissue of abdomen |
| | C49.5 | Malignant neoplasm of connective and soft tissue of pelvis |
| | C49.6 | Malignant neoplasm of connective and soft tissue of trunk, unspecified |
| C49.8 | Malignant neoplasm of overlapping sites of connective and soft tissue | |
| Drug: HCPCS | J9022 | Injection, atezolizumab, 10 mg |
| HCPCS: Modifier* Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded. | JW | Drug amount discarded/not administered to any patient |
| | JZ | Zero drug amount discarded/not administered to any patient |

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

*The JW modifier is required on claims for all single-dose container or single-use drugs when an amount is discarded. The JZ modifier is required to be used as of July 1, 2023. For more information on the JW and JZ modifiers, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

for **TECENTRIQ**[®]
(atezolizumab)

Alveolar Soft Part Sarcoma (ASPS) (cont)

| TYPE | CODE | | DESCRIPTION |
|--|--------------|---------------|---|
| | 10-digit | 11-digit | |
| Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 50242-917-01 | 50242-0917-01 | 1200 mg/20 mL single-dose vial |
| | 50242-918-01 | 50242-0918-01 | 840 mg/14 mL single-dose vial |
| | 96413 | | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| Administration procedures: CPT | 96415 | | Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) |
| | 96417 | | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) |

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

TECENTRIQ[®] is a registered trademark of Genentech, Inc.

Please see full [Prescribing Information](#) for Important Safety Information.